Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation
Clonal alterations in hematopoietic cells occur during aging and are often associated with
the establishment of a subclinical inflammatory environment. Several age-related conditions …
the establishment of a subclinical inflammatory environment. Several age-related conditions …
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
A Tefferi - Leukemia, 2010 - nature.com
Myeloproliferative neoplasms (MPNs) originate from genetically transformed hematopoietic
stem cells that retain the capacity for multilineage differentiation and effective myelopoiesis …
stem cells that retain the capacity for multilineage differentiation and effective myelopoiesis …
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
P Lundberg, A Karow, R Nienhold… - Blood, The Journal …, 2014 - ashpublications.org
Myeloproliferative neoplasms (MPNs) are a group of clonal disorders characterized by
aberrant hematopoietic proliferation and an increased tendency toward leukemic …
aberrant hematopoietic proliferation and an increased tendency toward leukemic …
Leukemia secondary to myeloproliferative neoplasms
AJ Dunbar, RK Rampal, R Levine - Blood, The Journal of the …, 2020 - ashpublications.org
Secondary acute myeloid leukemias (AMLs) evolving from an antecedent myeloproliferative
neoplasm (MPN) are characterized by a unique set of cytogenetic and molecular features …
neoplasm (MPN) are characterized by a unique set of cytogenetic and molecular features …
Two routes to leukemic transformation after a JAK2 mutation–positive myeloproliferative neoplasm
PA Beer, F Delhommeau, JP LeCouédic… - Blood, The Journal …, 2010 - ashpublications.org
Acute myeloid leukemia (AML) may follow a JAK2-positive myeloproliferative neoplasm
(MPN), although the mechanisms of disease evolution, often involving loss of mutant JAK2 …
(MPN), although the mechanisms of disease evolution, often involving loss of mutant JAK2 …
[HTML][HTML] Pathogenesis of myeloproliferative neoplasms
RC Skoda, A Duek, J Grisouard - Experimental hematology, 2015 - Elsevier
Major progress has been recently made in understanding the molecular pathogenesis of
myeloproliferative neoplasms (MPN). Mutations in one of four genes—JAK2, MPL, CALR …
myeloproliferative neoplasms (MPN). Mutations in one of four genes—JAK2, MPL, CALR …
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F–positive essential thrombocythemia
J Li, D Spensberger, JS Ahn, S Anand… - Blood, The Journal …, 2010 - ashpublications.org
The JAK2 V617F mutation is found in most patients with a myeloproliferative neoplasm and
is sufficient to produce a myeloproliferative phenotype in murine retroviral transplantation or …
is sufficient to produce a myeloproliferative phenotype in murine retroviral transplantation or …
Myeloid malignancies: mutations, models and management
A Murati, M Brecqueville, R Devillier, MJ Mozziconacci… - BMC cancer, 2012 - Springer
Myeloid malignant diseases comprise chronic (including myelodysplastic syndromes,
myeloproliferative neoplasms and chronic myelomonocytic leukemia) and acute (acute …
myeloproliferative neoplasms and chronic myelomonocytic leukemia) and acute (acute …
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms
FX Schaub, R Looser, S Li, H Hao-Shen… - Blood, The Journal …, 2010 - ashpublications.org
Somatic mutations in TET2 occur in patients with myeloproliferative neoplasms and other
hematologic malignancies. It has been suggested that TET2 is a tumor suppressor gene and …
hematologic malignancies. It has been suggested that TET2 is a tumor suppressor gene and …